Flotetuzumab - MacroGenics/Servier

Drug Profile

Flotetuzumab - MacroGenics/Servier

Alternative Names: CD123 x CD3; MGD 006; S 80880

Latest Information Update: 16 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MacroGenics
  • Developer MacroGenics; Servier
  • Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action CD3 antigen inhibitors; Immunomodulators; Interleukin-3-receptor-alpha-subunit-antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute myeloid leukaemia; Myelodysplastic syndromes

Most Recent Events

  • 07 Aug 2018 MacroGenics plans a phase I trial for Acute myeloid leukaemia (Combination therapy with MGA 012) in 2018
  • 07 May 2018 MacroGenics completes enrolment in dose expansion cohort in its phase I trial for Acute myeloid leukaemia
  • 18 Dec 2017 Phase-I development in Myelodysplastic-syndromes (Second-line therapy or greater) and in Acute-myeloid-leukaemia (Recurrent, Second-line therapy or greater, Treatment-resistant) is ongoing in Italy, France, USA (Parenteral) (NCT02152956)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top